MNPR Stock Analysis: Buy, Sell, or Hold?
MNPR - Monopar Therapeutics Inc. Common Stock
$60.38
-6.96 (-10.34%)
▼
5d:
-19.52%
30d:
-7.21%
90d:
-28.25%
WAIT
LOW Confidence
Last Updated: January 30, 2026
Get Alerted When MNPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MNPR is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MNPR is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MNPR is currently trading at $60.38, which is considered oversold relative to its 30-day fair value range of $63.45 to $70.74.
Technical Outlook: Technically, MNPR is showing sideways momentum. The price is currently testing key support at $60.28. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.3% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $112.00 (+85.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MNPR is showing sideways momentum. The price is currently testing key support at $60.28. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.3% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $112.00 (+85.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$63.45 -
$70.74
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.3%)
- BULLISH: Trading 85.5% below Wall St target ($112.00)
- WARNING: Recommendation downgraded due to -19.5% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$63.45 -
$70.74
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$60.28
Resistance Level
$76.13
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
-17.34
Wall Street Target
$112.00
(+85.5%)
Last updated: February 02, 2026 7:03 AM ET
Data refreshes hourly during market hours. Next update: 8:03 AM
Data refreshes hourly during market hours. Next update: 8:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Tactic Pharma Llc
SELL
550229 shares
2025-09-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
